Navigation Links
Aerolase Retains SMH Capital Inc. to Advise on Corporate Expansion
Date:9/19/2008

NEW YORK, Sept. 19 /PRNewswire/ -- Aerolase, the manufacturer of medical aesthetic lasers, announced today that it has retained SMH Capital Inc., a subsidiary of Sanders Morris Harris Group (Nasdaq: SMHG), as its financial advisor to explore financing alternatives to fund expansion into new markets.

The additional funding will be primarily directed toward expanding the Aerolase sales channel expansion into the market of about 300,000 U.S. primary care practitioners. This physician group is actively adding medical aesthetics to their practices to serve continuing strong demand for cosmetic-rejuvenation procedures, especially from affluent baby boomers.

"This is a unique opportunity for Aerolase," said CEO Dr. Pavel Efremkin. "Many physicians are now starting their new medical aesthetic practice, and YAG laser device is a "must-have" or "first-to-buy" laser for any medical aesthetic practitioner. Our LightPod Neo, because of its unique versatility, pain-free performance and portability, is undeniably the best YAG laser for this new market. With the expansion funding we will make LightPod the best selling medical laser on the market."

"We see tremendous potential for dramatic growth as medical aesthetic practitioners learn about the benefits of the LightPod Neo," said Mitchell Stern, Managing Director of SMH Capital Inc. "Aerolase is poised to capture a significant share of the aesthetic laser market over the next six to 12 months with sufficient funds to support expansion."

About Aerolase

Aerolase Corporation, Tarrytown, NY, is a world leader in the miniaturization of high-powered medical lasers. This core technology has been commercialized in the fields of medical & aesthetic dermatology as well as capillary blood testing and diabetes management.

The company's LightPod(R) lasers cover most aesthetic laser procedures on all skin types as well as many medical treatments. Aerolase lasers are packaged in the innovative LightPod system which utilizes air, rather than water, to continuously cool the internal laser emitter; this patented breakthrough resulted in a laser system that is portable and maintenance-free, also inherently less costly to manufacture and therefore more affordable. For more information, visit http://www.aerolase.com.

About Sanders Morris Harris Group

Sanders Morris Harris Group is a financial services company that manages $11 billion in client assets. It has two primary businesses. Asset/Wealth Management, the largest, provides highly regarded wealth advisory and asset management services to individuals and institutions. The other, Capital Markets, offers investment banking, institutional brokerage, trading, and research to a variety of institutions and middle market companies. Its corporate philosophy of investment in common aligns its interests with those of its clients. Sanders Morris Harris has over 600 employees in 21 states. Additional information is available at http://www.smhgroup.com.


'/>"/>
SOURCE Aerolase
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
2. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
3. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
4. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
5. Dragon retains leading investor relations firm
6. Interleukin Genetics Retains Top Life Science Communications Firms
7. SPO Medical Retains American Capital Ventures for Investor Relations Services
8. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
9. CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing
10. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
11. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
Breaking Biology News(10 mins):